Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity

Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, Takashi Niizeki, Takumi Kawaguchi

Clin Mol Hepatol. 2023;29(3):593-604. Published online February 13, 2023

DOI: https://doi.org/10.3350/cmh.2022.0391

View: 4579 Download: 350 Web of Science: 11 Crossref: 9

Editorial

Can metronomic chemotherapy be an alternative to sorafenib in advanced hepatocellular carcinoma?

Do Young Kim

Clin Mol Hepatol. 2017;23(2):123-124. Published online June 23, 2017

DOI: https://doi.org/10.3350/cmh.2017.0107

View: 7138 Download: 119

Original Article

Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as first-line therapy

Myung Jin Oh, Heon Ju Lee, Si Hyung Lee

Clin Mol Hepatol. 2013;19(3):288-299. Published online September 30, 2013

DOI: https://doi.org/10.3350/cmh.2013.19.3.288

View: 8651 Download: 75 Crossref: 10

A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma

Hee Yeon Kim, Jin Dong Kim, Si Hyun Bae, Jun Yong Park, Kwang Hyub Han, Hyun Young Woo, Jong Young Choi, Seung Kew Yoon, Byoung Kuk Jang, Jae Seok Hwang, Sang Gyune Kim, Young Seok Kim, Yeon Seok Seo, Hyung Joon Yim, Soon Ho Um, Korean Liver Cancer Study Group

Clin Mol Hepatol. 2010;16(4):355-361. Published online December 31, 2010

DOI: https://doi.org/10.3350/kjhep.2010.16.4.355

View: 9031 Download: 87 Crossref: 41

Editorial

Which treatment modality should we choose for advanced hepatocellular carcinoma?

Do Young Kim

Clin Mol Hepatol. 2010;16(4):353-354. Published online December 31, 2010

DOI: https://doi.org/10.3350/kjhep.2010.16.4.353

View: 6091 Download: 63

1 |

Viewed By 6029	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 5559	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 5356	MAFLD: How is it different from NAFLD?
Viewed By 5326	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4904	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 208	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 146	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 119	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 109	MAFLD: How is it different from NAFLD?
Cited By 94	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search